The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa
Abstract
Background: Anderson–Fabry disease is an X-linked glycosphingolipid storage disorder caused by deficient activity of the lysosomal enzyme α-galactosidase A. This leads to a progressive accumulation of globotriaosylceramide (Gb 3) in the lysosomes of cells throughout the body that ultimately results in premature death from renal, cardiac or cerebrovascular complications. Until recently, there was no effective therapy available for this disease. The present study was designed to assess the safety and efficacy of enzyme replacement therapy with agalsidase alfa on the cardiac manifestations of Anderson–Fabry disease. Method: The effects of therapy with agalsidase alfa on cardiac structure and function were assessed in a randomised, double-blind, placebo-controlled study of 15 adult male patients with Anderson–Fabry disease. The following parameters were measured at baseline and 6 months: left ventricular mass, QRS duration and levels of Gb 3 in cardiac tissue, urine sediment and plasma. After 6 months of the randomised trial patients were enrolled in a 2-year open-label extension study. Results: Left ventricular mass, as measured by MRI, was significantly reduced following 6 months of treatment with agalsidase alfa compared with placebo (p = 0.041). A mean 20% reduction in myocardial Gb 3 content as assessed by serial transvenous endomyocardial biopsies was demonstrated over the 6 months of enzyme replacement compared to a mean 10% increase in patients receiving placebo (p = 0.42) Conclusion: Enzyme replacement therapy with agalsidase alfa resulted in regression of the hypertrophic cardiomyopathy associated with Anderson–Fabry disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings
Devereux, R. B., Alonso, D. R., Lutas, E. M., Gottlieb, G. J., Campo, E., Sachs, I., & Reichek, N. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90771-x · Cited by 6,229
Koren, M. J., Devereux, R. B., Casale, P. N., Savage, D. D., & Laragh, J. H. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-5-345 · Cited by 2,366
Prevalence of lysosomal storage disorders
Meikle, P. J. (1999) · JAMA · doi:10.1001/jama.281.3.249 · Cited by 2,197
Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease
Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., Caplan, L., Linthorst, G. E., & Desnick, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450102 · Cited by 1,559
Enzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial
Schiffmann, R., Kopp, J. B., Austin III, H. A., Sabnis, S., Moore, D. F., Weibel, T., Balow, J. E., & Brady, R. O. (2001) · JAMA · doi:10.1001/jama.285.21.2743 · Cited by 1,302
Enzymatic Defect in Fabry's Disease: Ceramidetrihexosidase Deficiency
Brady, R. O., Gal, A. E., Bradley, R. M., Martensson, E., Warshaw, A. L., & Laster, L. (1967) · New England Journal of Medicine · doi:10.1056/nejm196705252762101 · Cited by 1,053
High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*
Spada, M., Pagliardini, S., Yasuda, M., Tukel, T., Thiagarajan, G., Sakuraba, H., Ponzone, A., & Desnick, R. J. (2006) · The American Journal of Human Genetics · doi:10.1086/504601 · Cited by 1,008
An Atypical Variant of Fabry's Disease in Men with Left Ventricular Hypertrophy
Nakao, S., Takenaka, T., Maeda, M., Kodama, C., Tanaka, A., Tahara, M., Yoshida, A., Kuriyama, M., Hayashibe, H., Sakuraba, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508033330504 · Cited by 763
The frequency of lysosomal storage diseases in The Netherlands
Poorthuis, B. J. H. M., Wevers, R. A., Kleijer, W. J., Groener, J. E. M., de Jong, J. G. N., van Weely, S., Niezen-Koning, K. E., & van Diggelen, O. P. (1999) · Human Genetics · doi:10.1007/s004390051078 · Cited by 720
α-Galactosidase A deficiency. Fabry disease
Desnick, R. J. (2001) · Cited by 605
Prevalence of Anderson-Fabry Disease in Male Patients With Late Onset Hypertrophic Cardiomyopathy
Sachdev, B., Takenaka, T., Teraguchi, H., Tei, C., Lee, P., McKenna, W. J., & Elliott, P. M. (2002) · Circulation · doi:10.1161/01.cir.0000012626.81324.38 · Cited by 570
Self-citationAn Atypical Variant of Fabry's Disease with Manifestations Confined to the Myocardium
Scheidt, W. V., Eng, C. M., Fitzmaurice, T. F., Erdmann, E., Hübner, G., Olsen, E. G. J., Christomanou, H., Kandolf, R., Bishop, D. F., & Desnick, R. J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102073240607 · Cited by 371
Schiffmann, R., Murray, G. J., Treco, D., Daniel, P., Sellos-Moura, M., Myers, M., Quirk, J. M., Zirzow, G. C., Borowski, M., Loveday, K., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.365 · Cited by 342
Cited by
Germain, D. P. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-30 · Cited by 1,198
Sado, D. M., White, S. K., Piechnik, S. K., Banypersad, S. M., Treibel, T., Captur, G., Fontana, M., Maestrini, V., Flett, A. S., Robson, M. D., et al. (2013) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.112.000070 · Cited by 541
Self-citationWeidemann, F., Niemann, M., Breunig, F., Herrmann, S., Beer, M., Störk, S., Voelker, W., Ertl, G., Wanner, C., & Strotmann, J. (2009) · Circulation · doi:10.1161/circulationaha.108.794529 · Cited by 488
The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure
Karamitsos, T. D., Francis, J. M., Myerson, S., Selvanayagam, J. B., & Neubauer, S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.094 · Cited by 467
Waldek, S., Patel, M. R., Banikazemi, M., Lemay, R., & Lee, P. (2009) · Genetics in Medicine · doi:10.1097/gim.0b013e3181bb05bb · Cited by 353
Metadata
- Authors
- Hughes, D. A., Elliott, P. M., Shah, J., Zuckerman, J., Coghlan, G., Brookes, J., & Mehta, A. B.
- Venue
- Heart
- Publisher
- BMJ
- Published
- 2007-05-04
- Volume
- 94
- Issue
- 2
- Pages
- 153-158
- ISSN
- 1355-6037 (ISSN-L)
- 1468-201X
- OpenAlex
- W2139927163
- Cited by
- 318
- References
- 13
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.